Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized withdrawal study of subcutaneous IBI112 in moderate-to-severe plaque psoriasis
CTR20232958Phase 3Completed
- Sponsor
- InnoCare Pharma
- Start
- Sep 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of picankibart in plaque psoriasis, sponsored by InnoCare Pharma. Started Sep 2023; status: completed.
02
Drugs
picankibart
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on CTR20232958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232958.